Results 1 to 10 of about 2,162,821 (172)

Kidney age, not kidney disease [PDF]

Canadian Medical Association Journal, 2018
KEY POINTS Although a variety of conditions and syndromes may affect the kidneys over either chronic or acute time frames, the term “chronic kidney disease” (CKD) is used to describe a decrease in the filtration ability of the glomerular capillaries in the kidney.
Stevens, Richard J, Evans, Julie, Oke, Jason, Smart, Benjamin, Hobbs, Richard, Holloway, Elizabeth, Horwood, Jeremy, Judd, Marion, Locock, Louise, McLellan, Julie, Perera, Rafael   +10 more
openaire   +7 more sources

Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association

Circulation, 2023
Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system and has profound impacts on morbidity and mortality.
C. Ndumele, J. Rangaswami, Sheryl L Chow, I. Neeland, Katherine Tuttle, Sadiya S. Khan, J. Coresh, Roy O Mathew, C. Baker-Smith, M. Carnethon, Jean-Pierre Després, Jennifer E Ho, Joshua J Joseph, Walter N Kernan, Amit Khera, Mikhail N. Kosiborod, Carolyn L. Lekavich, Eldrin F. Lewis, Kevin B Lo, Bige Ozkan, Latha P. Palaniappan, Sonali S Patel, Michael J. Pencina, Tiffany Powell-wiley, Laurence S Sperling, Salim S. Virani, Jackson T Wright, Radhika Rajgopal Singh, Mitchell S. V. Elkind   +28 more
semanticscholar   +1 more source

Dapagliflozin in Patients with Chronic Kidney Disease.

New England Journal of Medicine, 2020
BACKGROUND Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.
H. Heerspink, B. Stefánsson, R. Correa-Rotter, G. Chertow, T. Greene, F. Hou, J. Mann, J. McMurray, M. Lindberg, P. Rossing, C. Sjöström, R. Toto, A. Langkilde, D. Wheeler   +13 more
semanticscholar   +1 more source

Empagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine, 2022
Background This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. Methods We randomly assigned 6609 participants to empagliflozin (10mg
W. Herrington, N. Staplin, C. Wanner, J. B. Green, S. Hauske, J. Emberson, D. Preiss, P. Judge, Kaitlin J. Mayne, S. Ng, E. Sammons, D. Zhu, M. Hill, W. Stevens, K. Wallendszus, S. Brenner, A. Cheung, Zhi-Hong Liu, Jing Li, L. Hooi, Wen Liu, T. Kadowaki, M. Nangaku, A. Levin, D. Cherney, A. Maggioni, R. Pontremoli, R. Deo, S. Goto, X. Rosselló, K. Tuttle, D. Steubl, M. Petrini, D. Massey, Jens Eilbracht, M. Brueckmann, M. Landray, C. Baigent, R. Haynes   +38 more
semanticscholar   +1 more source

Kidney: polycystic kidney disease [PDF]

WIREs Developmental Biology, 2014
Polycystic kidney disease (PKD) is a life‐threatening genetic disorder characterized by the presence of fluid‐filled cysts primarily in the kidneys. PKD can be inherited as autosomal recessive (ARPKD) or autosomal dominant (ADPKD) traits. Mutations in either the PKD1 or PKD2 genes, which encode polycystin 1 and polycystin 2, are the underlying cause of
Gregory B. Vanden Heuvel, Gregory B. Vanden Heuvel, Binu M. Paul   +2 more
openaire   +3 more sources

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

Diabetes Care, 2022
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent clinical trials support new approaches to treat diabetes and CKD.
I. D. de Boer, K. Khunti, Tami Sadusky, K. Tuttle, Joshua J. Neumiller, Connie M. Rhee, Sylvia E. Rosas, P. Rossing, G. Bakris   +8 more
semanticscholar   +1 more source

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy.
R. Motzer, E. Jonasch, N. Agarwal, A. Alva, M. Baine, Kathryn E. Beckermann, M. Carlo, T. Choueiri, B. Costello, I. Derweesh, A. Desai, Yasser Ged, S. George, J. Gore, N. Haas, S. Hancock, Payal Kapur, Christos Kyriakopoulos, E. Lam, P. Lara, C. Lau, Bryan Lewis, D. Madoff, B. Manley, M. Michaelson, A. Mortazavi, L. Nandagopal, E. Plimack, L. Ponsky, Sundhar Ramalingam, B. Shuch, Z. Smith, J. Sosman, M. Dwyer, Lisa A. Gurski, Angela Motter   +35 more
semanticscholar   +1 more source

Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

PLoS ONE, 2016
Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems and is an independent risk factor for cardiovascular disease (CVD).
N. Hill, Samuel T. Fatoba, J. Oke, J. Hirst, C. O'Callaghan, D. Lasserson, F. R. Hobbs   +6 more
semanticscholar   +1 more source

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

Critical Care, 2007
IntroductionAcute kidney injury (AKI) is a complex disorder for which currently there is no accepted definition. Having a uniform standard for diagnosing and classifying AKI would enhance our ability to manage these patients.
R. Mehta, J. Kellum, Sudhir V. Shah, B. Molitoris, C. Ronco, D. Warnock, A. Levin   +6 more
semanticscholar   +1 more source

A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.

American Journal of Kidney Diseases, 2021
BACKGROUND In response to a national call for reevaluation of the use of race in clinical algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a Task Force to reassess inclusion of race in the ...
C. Delgado, Mukta Baweja, D. Crews, N. Eneanya, C. Gadegbeku, L. Inker, Mallika L Mendu, W. Miller, M. Moxey-Mims, Glenda V Roberts, W. S. St. Peter, Curtis Warfield, N. Powe   +12 more
semanticscholar   +1 more source